Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...
Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...
Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback